Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cgp 39393
2. Cgp-39393
3. Desulfatohirudin
4. Desulphatohirudin
5. Ik-hir02
6. Iprivask
7. Recombinant Hv1 Hirudin
8. Revasc
1. Cgp 39393
2. Cgp-39393
3. 120993-53-5
4. Desirudin [usan:inn:ban]
5. Unii-u0jz726775
6. Gtpl6458
7. Hirudin (hirudo Medicinalis Isoform Hv1), 63-desulfo-
8. Dtxsid90153094
9. Cgp39393
10. U0jz726775
| Molecular Weight | 6963 g/mol |
|---|---|
| Molecular Formula | C287H440N80O110S6 |
| XLogP3 | -40.1 |
| Hydrogen Bond Donor Count | 99 |
| Hydrogen Bond Acceptor Count | 121 |
| Rotatable Bond Count | 165 |
| Exact Mass | 6961.9720340 g/mol |
| Monoisotopic Mass | 6958.9619695 g/mol |
| Topological Polar Surface Area | 3240 Ų |
| Heavy Atom Count | 483 |
| Formal Charge | 0 |
| Complexity | 18600 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 62 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Iprivask |
| PubMed Health | Desirudin (Injection) |
| Drug Classes | Anticoagulant |
| Active Ingredient | Desirudin recombinant |
| Dosage Form | Injectable |
| Route | Subcutaneous |
| Strength | 15mg/vial |
| Market Status | Prescription |
| Company | Marathon Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Iprivask |
| PubMed Health | Desirudin (Injection) |
| Drug Classes | Anticoagulant |
| Active Ingredient | Desirudin recombinant |
| Dosage Form | Injectable |
| Route | Subcutaneous |
| Strength | 15mg/vial |
| Market Status | Prescription |
| Company | Marathon Pharms |
Indicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.
Desirudin results in dose-dependent prolongation of the activated partial thromboplastin time (aPTT).
Anticoagulants
Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)
Fibrinolytic Agents
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)
B01AE01
B - Blood and blood forming organs
B01 - Antithrombotic agents
B01A - Antithrombotic agents
B01AE - Direct thrombin inhibitors
B01AE01 - Desirudin
Absorption
Absorption is complete after subcutaneous administration. Time to peak in plasma is 1 to 3 hours.
Route of Elimination
Urine (40% to 50% as unchanged drug).
Volume of Distribution
0.25 L/kg.
Clearance
1.5 to 2.7 mL/min/kg.
Human and animal data suggest that desirudin is primarily eliminated and metabolized by the kidney. The total urinary excretion of unchanged desirudin amounts to 40 to 50% of the administered dose. Metabolites lacking one or two C-terminal amino acids constitute a minor proportion of the material recovered from urine (< 7%). There is no evidence for the presence of other metabolites. This indicates that desirudin is metabolized by stepwise degradation from the C-terminus probably catalyzed by carboxypeptidase(s) such as carboxypeptidase A.
~2 hours.
Desirudin is a direct, highly selective thrombin inhibitor. Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation, activation of coagulation factors V, VII, and XIII, and thrombin-induced platelet aggregation resulting in a dose-dependent prolongation of the activated partial thromboplastin time (aPTT).
Related Excipient Companies
Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Taste Masking
Thickeners and Stabilizers
Parenteral
Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
95
PharmaCompass offers a list of Desirudin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Desirudin manufacturer or Desirudin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Desirudin manufacturer or Desirudin supplier.
PharmaCompass also assists you with knowing the Desirudin API Price utilized in the formulation of products. Desirudin API Price is not always fixed or binding as the Desirudin Price is obtained through a variety of data sources. The Desirudin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DESIRUDIN RECOMBINANT manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DESIRUDIN RECOMBINANT, including repackagers and relabelers. The FDA regulates DESIRUDIN RECOMBINANT manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DESIRUDIN RECOMBINANT API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A DESIRUDIN RECOMBINANT supplier is an individual or a company that provides DESIRUDIN RECOMBINANT active pharmaceutical ingredient (API) or DESIRUDIN RECOMBINANT finished formulations upon request. The DESIRUDIN RECOMBINANT suppliers may include DESIRUDIN RECOMBINANT API manufacturers, exporters, distributors and traders.
DESIRUDIN RECOMBINANT Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DESIRUDIN RECOMBINANT GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DESIRUDIN RECOMBINANT GMP manufacturer or DESIRUDIN RECOMBINANT GMP API supplier for your needs.
A DESIRUDIN RECOMBINANT CoA (Certificate of Analysis) is a formal document that attests to DESIRUDIN RECOMBINANT's compliance with DESIRUDIN RECOMBINANT specifications and serves as a tool for batch-level quality control.
DESIRUDIN RECOMBINANT CoA mostly includes findings from lab analyses of a specific batch. For each DESIRUDIN RECOMBINANT CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DESIRUDIN RECOMBINANT may be tested according to a variety of international standards, such as European Pharmacopoeia (DESIRUDIN RECOMBINANT EP), DESIRUDIN RECOMBINANT JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DESIRUDIN RECOMBINANT USP).
